Intranasal NAC Delivery for Blood-Brain Barrier Bypass
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for mild traumatic brain injuries (mTBIs) face challenges due to poor systemic availability and oral bioavailability of N-acetylcysteine (NAC), which results in insufficient brain penetrability and bioactivity, and the difficulty in crossing the blood-brain barrier.
Innovation Solution
Intranasal administration of NAC or its congeners to bypass the blood-brain barrier, allowing direct delivery to the brain through multiple pathways, including the olfactory and trigeminal nerves, without significant systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oral administration of NAC is used, then systemic availability is improved, but brain penetrability and bioactivity remain insufficient due to poor oral bioavailability
Solution Approach 1:
The patent uses the olfactory nerve as an intermediary pathway to transport NAC from the nasal cavity directly to the brain, bypassing the blood-brain barrier. This mediator approach allows the substance to cross biological barriers that would otherwise be impermeable to it.
Solution Approach 2:
The patent transitions from oral administration (systemic circulation pathway) to intranasal administration (direct neural pathway), changing the dimensional route of delivery from blood-borne to nerve-borne transport, thereby achieving direct brain penetration without relying on systemic circulation.
2Reliability
If intranasal administration is used to bypass blood-brain barrier, then brain penetration is improved, but systemic exposure is minimized which may reduce overall bioavailability
Solution Approach 1:
The patent extracts NAC from the systemic circulation pathway and delivers it directly to the brain through the olfactory nerve, separating the brain delivery function from the systemic circulation function. This extraction allows high brain concentrations without requiring high systemic exposure.
3Adaptability or versatility
If NAC is administered systemically, then widespread distribution is achieved, but blood-brain barrier prevents sufficient brain delivery
Solution Approach 1:
The patent segments the delivery system into two independent pathways: systemic circulation for widespread distribution and the olfactory nerve pathway for direct brain delivery. This segmentation allows each pathway to serve its specific function optimally without interfering with the other.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves therapeutically-effective brain penetration of NAC, bypassing systemic circulation and the blood-brain barrier, thereby providing antioxidant and anti-inflammatory effects for treating brain disorders.
Implementation Method 1
the NAC, or the congener thereof, crosses an olfactory epithelium of the subject after the intranasal administration, and then after crossing the olfactory epithelium, the NAC, or the congener thereof, enters an olfactory nerve of the subject
Implementation Method 2
the NAC, or the congener thereof, crosses a respiratory or olfactory epithelium, the NAC traverses the nasal rostral migratory stream pathway, and then after traversing the rostral migratory stream pathway, enters the brain
Data Source
AI summary
The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.